David Schwartz of the Illinois Institute of Technology-Chicago, Kent College of Law, discusses the impact of the US Supreme Court unanimously striking down Myriad Genetics' patent of human BRCA genes and tests to detect mutations in them.
Last week’s Supreme Court decision to invalidate patents on human genes was a win for patients, independent researchers, and even the wider biotech industry.